In this episode, Drs. Erin Michos and Christie Ballantyne examine the importance of testing and identifying lipoprotein(a) ( Lp[a]) levels in patients, research highlighting trends in populations at risk, and the genetic factors involved in assessment. The significance associated with various levels of Lp(a) in measurement and how testing plays a role in management is also discussed. This CardiaCast episode is part of an ACC course titled Elevating Lp(a) Awareness: Bridging the CVD Risk Knowledge Gap. Educational grant support is provided by Novartis. To visit the Online Course page for the Elevating Lp(a) Awareness: Bridging the CVD Risk Knowledge Gap Grant, click here!
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
Before the Crisis: How You and Your Relatives Can Prepare for Financial Caregiving
06 Dec 2025
Motley Fool Money
OpenAI's Code Red, Sacks vs New York Times, New Poverty Line?
06 Dec 2025
All-In with Chamath, Jason, Sacks & Friedberg
OpenAI's Code Red, Sacks vs New York Times, New Poverty Line?
06 Dec 2025
All-In with Chamath, Jason, Sacks & Friedberg
Anthropic Finds AI Answers with Interviewer
05 Dec 2025
The Daily AI Show
#2423 - John Cena
05 Dec 2025
The Joe Rogan Experience
Warehouse to wellness: Bob Mauch on modern pharmaceutical distribution
05 Dec 2025
McKinsey on Healthcare